Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

66 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ. Press MF, et al. J Clin Oncol. 2011 Mar 1;29(7):859-67. doi: 10.1200/JCO.2009.27.5644. Epub 2010 Dec 28. J Clin Oncol. 2011. PMID: 21189395 Free PMC article. Clinical Trial.
Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
Konecny GE, Pauletti G, Untch M, Wang HJ, Möbus V, Kuhn W, Thomssen C, Harbeck N, Wang L, Apple S, Jänicke F, Slamon DJ. Konecny GE, et al. Breast Cancer Res Treat. 2010 Apr;120(2):481-9. doi: 10.1007/s10549-010-0744-z. Epub 2010 Feb 4. Breast Cancer Res Treat. 2010. PMID: 20130985
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
Konecny GE, Thomssen C, Lück HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Möbus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Jänicke F, Slamon DJ. Konecny GE, et al. J Natl Cancer Inst. 2004 Aug 4;96(15):1141-51. doi: 10.1093/jnci/djh198. J Natl Cancer Inst. 2004. PMID: 15292386
Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors.
Namazie A, Alavi S, Olopade OI, Pauletti G, Aghamohammadi N, Aghamohammadi M, Gornbein JA, Calcaterra TC, Slamon DJ, Wang MB, Srivatsan ES. Namazie A, et al. Laryngoscope. 2002 Mar;112(3):472-81. doi: 10.1097/00005537-200203000-00013. Laryngoscope. 2002. PMID: 12148857
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. Konecny G, et al. J Natl Cancer Inst. 2003 Jan 15;95(2):142-53. doi: 10.1093/jnci/95.2.142. J Natl Cancer Inst. 2003. PMID: 12529347
Early appearance and long-term persistence of the submicroscopic extrachromosomal elements (amplisomes) containing the amplified DHFR genes in human cell lines.
Pauletti G, Lai E, Attardi G. Pauletti G, et al. Proc Natl Acad Sci U S A. 1990 Apr;87(8):2955-9. doi: 10.1073/pnas.87.8.2955. Proc Natl Acad Sci U S A. 1990. PMID: 2326258 Free PMC article.
HER-2/neu as a predictive marker of response to breast cancer therapy.
Pegram MD, Pauletti G, Slamon DJ. Pegram MD, et al. Breast Cancer Res Treat. 1998;52(1-3):65-77. doi: 10.1023/a:1006111117877. Breast Cancer Res Treat. 1998. PMID: 10066073 Review.
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ. Pauletti G, et al. J Clin Oncol. 2000 Nov 1;18(21):3651-64. doi: 10.1200/JCO.2000.18.21.3651. J Clin Oncol. 2000. PMID: 11054438
Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.
Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, Pauletti G, Powell JE, Pegram MD, Slamon DJ. Hurley J, et al. J Clin Oncol. 2006 Apr 20;24(12):1831-8. doi: 10.1200/JCO.2005.02.8886. Epub 2006 Mar 20. J Clin Oncol. 2006. PMID: 16549824 Clinical Trial.
66 results
Jump to page